comprehensive -WSS

comprehensive

author：explore 2025-09-30 00:39:49 - browse：3233

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： ACIP vaccine advisory panel sees its vacancies filled

leisure time

WSS

Stem cell biologist probes earliest stages of human development

For AI in health care standards, federal regulators join with industry group

Study gives hint on South Asians’ higher risk of cardiovascular disease

Study gives hint on South Asians’ higher risk of cardiovascular disease

A new approach to psychiatric drug development

Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

comprehensive

focus

Affirmative action in medical school literally saved lives

Bernie Sanders gets little from pharma CEOs on drug prices

The high cost of giving birth even with insurance

Ozempic has benefits for kidney disease as well as diabetes

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Harvard's David Sinclair gets blowback over aging

Alkermes shareholders re

Ozempic has benefits for kidney disease as well as diabetes

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

hotspot

Pregnant women don't need prenatal multivitamins, study concludes

Fetal cell organoids grown from amniotic fluid, study finds

For AI in health care standards, federal regulators join with industry group

Fetal cell organoids grown from amniotic fluid, study finds

Congress considering partial increase for doctor pay in Medicare

State of the Union pitch: Bigger Medicare drug price negotiations

leisure time

hotspot

leisure time

hotspot